Sponsor content
380 result(s) found, displaying 51 to 60
-
Australian public assessment report (AusPar)Exarane/Exarane Forte (enoxaparin sodium) has been approved for the prevention of thrombo-embolic disorders, thrombosis and prophylaxis of venous thromboembolism. It has also been approved for the treatment of deep vein thrombosis, unstable angina, non-Q-wave myocardial infarction and acute ST-segment elevation myocardial infarction.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for DEXAMETHASONE JUNO dexamethasone phosphate (as dexamethasone sodium phosphate) 4 mg/1 mL solution for injection ampoule.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for DEXAMETHASONE JUNO dexamethasone phosphate (as dexamethasone sodium phosphate) 8 mg/2 mL solution for injection ampoule.
-
Prescription medicine registrationActive ingredients: testosterone undecanoate.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ESMOLOL JUNO esmolol hydrochloride 100 mg/10 mL solution for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for FENTANYL JUNO fentanyl (as citrate) 500 microgram/10 mL injection ampoule.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for FENTANYL JUNO fentanyl (as citrate) 100 microgram/2 mL injection ampoule.
-
Prescription medicine registrationActive ingredients: fosaprepitant dimeglumine.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ATROPINE JUNO atropine sulfate monohydrate 600 microgram/1mL injection BP ampoule.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ATROPINE JUNO atropine sulfate monohydrate 1.2mg/1mL injection BP ampoule.